Search peptides, terms, sources/
7 peptides

Metabolic and incretin

Metabolic and incretin peptides act on the gut-hormone systems that help control blood sugar, appetite and body weight. The group includes GLP-1, GIP, glucagon and amylin-pathway compounds. Some are UK prescription-only medicines and others are still investigational. Each peptide's evidence is graded separately, so being in this group says nothing about how well any one of them works.

Which peptides are in this family?

  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Survodutide

    Investigational peptide that activates glucagon and GLP-1 receptors. Not authorised in the UK. Studied in phase 3 trials, all sponsor-funded.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

Best recorded finding for each peptide in this family

Each row grades one recorded finding, not the peptide or the medicine.

PeptideUK statusFindingEvidence grade
CagrilintideNot licensed in the UKStandalone Phase 2 weight trialModerate
LiraglutideLicensed UK medicineSCALE prediabetes progression trialModerate
MazdutideNot licensed in the UKGLORY-1, phase 3 in ChinaStrong
RetatrutideNot licensed in the UKPhase 2 obesity trialModerate
SemaglutideLicensed UK medicineWeight change at 68 weeksStrong
SurvodutideNot licensed in the UKPhase 3 in obesity without diabetesStrong
TirzepatideLicensed UK medicineThe SURMOUNT-1 obesity trialStrong

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.